Baroda BNP Paribas Mutual FundEquity Scheme - Sectoral/ Thematic2.3 years
The scheme to generate long-term capital appreciation from a portfolio invested predominantly in equity and equity related securities of companies engaged in the Manufacturing. The Scheme does not guarantee/indicate any returns. There is no assurance that the investment objective of the Scheme will be achieved.
Buying brief
Evidence on this desk, framed as a purchase checklist - not SEBI-registered advice.
As of 29 Oct 2026
Stance
Watch before adding
Recent evidence is mixed. Compare peers before increasing exposure.
In three lines
Fits if · The fund beat the category median in 83% of rolling 1-year windows.
Prefer peers if · Prefer Kotak Business Cycle Fund if you want a same-category peer with stronger evidence.
Buy checklist
History depth
Fail
2.3 years - thin for judging consistency.
Engine status
Watch
Recent evidence is mixed. Compare peers before increasing exposure.
Expense ratio
Pass
1.31% TER (Direct). Lower cost compounds on long SIPs.
Drawdown vs peers
Pass
Peak-to-trough -22.0%. Ask whether you can hold through a similar fall.
Vs category
n/a
Category relative read still thin.
Manager tenure
Watch
Himanshu Singh · 0.3 years on the scheme.
Exit load
n/a
No exit-load summary on file.
Tax / wrapper
Pass
Direct Growth, no ELSS lock flagged. Equity LTCG rules still apply after one year - not tax advice.
Portfolio concentration
Pass
Top 10 holdings ≈ 45.5% of the portfolio.
Same-category peers are preloaded into compare when available.
Behaviour and wrappers - the usual India MF failure modes - not a buy instruction.
Drawdown rehearsal
This scheme’s worst fall on file is about 22%. Before you SIP, ask whether you would keep contributing through a similar drop - pausing on fear is the usual India MF failure mode.
SIP discipline
Monitor is recent mixed evidence - keep the SIP unless the buying brief says prefer peers, then swap with intent.
NAV
Path not in current snapshots
n/a
Trailing CAGR and simulated monthly SIP XIRR from daily NAV. Category comparison uses the median of comparable share classes in the peer set.
Trailing CAGR
Point-to-point, calendar-day annualized
SIP XIRR
Equal monthly instalments to latest NAV
Peak to trough from a running NAV high, with the path and recovery episodes.
Drawdown
Path not in current snapshots
n/a
27 Sept 2024 – 2 Jan 2026
Trough 28 Feb 2025 · recovered in 308 days
-22.0%
12 Aug 2026 – open
Trough 23 Oct 2026 · not recovered
-13.9%
26 Feb 2026 – 22 Apr 2026
Trough 31 Mar 2026 · recovered in 22 days
-9.9%
7 May 2026 – 31 Jul 2026
Trough 11 Jun 2026 · recovered in 50 days
-6.2%
0–100 reads of named metrics. The mean is unweighted and only uses dimensions with data.
Returns
29
Vs category
86
Consistency
83
Risk-adjusted
14
Drawdown
45
Mean
51
Quantitative engine reasons behind the buying stance. An explanation can only restate what is already here.
Buying stance
Watch before adding
Recent evidence is mixed. Compare peers before increasing exposure.
Why this status
Supporting reads
30 Sept 2026 · 44 holdings · top 10 are 45.5%.
Divi's Laboratories Ltd
Healthcare
7.7%
Hitachi Energy India Ltd
Industrials
5.9%
Bharat Heavy Electricals Ltd
Industrials
5.7%
Reliance Industries Ltd
Energy & Utilities
5.2%
Sun Pharmaceutical Industries Ltd
Healthcare
4.8%
PERFORMANCE
Recent rolling excess versus the category median has deteriorated.
16 Oct 2026
Same-category peers with enough history to inspect beside this fund - including tradeoffs.
Kotak Mahindra Mutual Fund
Nippon India Mutual Fund
ICICI Prudential Mutual Fund
Motilal Oswal Mutual Fund
Caveat: Higher volatility · Higher TER
Aditya Birla Sun Life Mutual Fund
Caveat: Higher TER
Baroda BNP Paribas Mutual FundEquity Scheme - Sectoral/ Thematic2.3 years
The scheme to generate long-term capital appreciation from a portfolio invested predominantly in equity and equity related securities of companies engaged in the Manufacturing. The Scheme does not guarantee/indicate any returns. There is no assurance that the investment objective of the Scheme will be achieved.
Buying brief
Evidence on this desk, framed as a purchase checklist - not SEBI-registered advice.
As of 29 Oct 2026
Stance
Watch before adding
Recent evidence is mixed. Compare peers before increasing exposure.
In three lines
Fits if · The fund beat the category median in 83% of rolling 1-year windows.
Prefer peers if · Prefer Kotak Business Cycle Fund if you want a same-category peer with stronger evidence.
Buy checklist
History depth
Fail
2.3 years - thin for judging consistency.
Engine status
Watch
Recent evidence is mixed. Compare peers before increasing exposure.
Expense ratio
Pass
1.31% TER (Direct). Lower cost compounds on long SIPs.
Drawdown vs peers
Pass
Peak-to-trough -22.0%. Ask whether you can hold through a similar fall.
Vs category
n/a
Category relative read still thin.
Manager tenure
Watch
Himanshu Singh · 0.3 years on the scheme.
Exit load
n/a
No exit-load summary on file.
Tax / wrapper
Pass
Direct Growth, no ELSS lock flagged. Equity LTCG rules still apply after one year - not tax advice.
Portfolio concentration
Pass
Top 10 holdings ≈ 45.5% of the portfolio.
Same-category peers are preloaded into compare when available.
Behaviour and wrappers - the usual India MF failure modes - not a buy instruction.
Drawdown rehearsal
This scheme’s worst fall on file is about 22%. Before you SIP, ask whether you would keep contributing through a similar drop - pausing on fear is the usual India MF failure mode.
SIP discipline
Monitor is recent mixed evidence - keep the SIP unless the buying brief says prefer peers, then swap with intent.
NAV
29 Oct 2026 · +3.2% over 1Y
10.4478
Trailing CAGR and simulated monthly SIP XIRR from daily NAV. Category comparison uses the median of comparable share classes in the peer set.
Trailing CAGR
Point-to-point, calendar-day annualized
SIP XIRR
Equal monthly instalments to latest NAV
Peak to trough from a running NAV high, with the path and recovery episodes.
Drawdown
29 Oct 2026
-11.5%
27 Sept 2024 – 2 Jan 2026
Trough 28 Feb 2025 · recovered in 308 days
-22.0%
12 Aug 2026 – open
Trough 23 Oct 2026 · not recovered
-13.9%
26 Feb 2026 – 22 Apr 2026
Trough 31 Mar 2026 · recovered in 22 days
-9.9%
7 May 2026 – 31 Jul 2026
Trough 11 Jun 2026 · recovered in 50 days
-6.2%
0–100 reads of named metrics. The mean is unweighted and only uses dimensions with data.
Returns
29
Vs category
86
Consistency
83
Risk-adjusted
14
Drawdown
45
Mean
51
Quantitative engine reasons behind the buying stance. An explanation can only restate what is already here.
Buying stance
Watch before adding
Recent evidence is mixed. Compare peers before increasing exposure.
Why this status
Supporting reads
30 Sept 2026 · 44 holdings · top 10 are 45.5%.
Divi's Laboratories Ltd
Healthcare
7.7%
Hitachi Energy India Ltd
Industrials
5.9%
Bharat Heavy Electricals Ltd
Industrials
5.7%
Reliance Industries Ltd
Energy & Utilities
5.2%
Sun Pharmaceutical Industries Ltd
Healthcare
4.8%
PERFORMANCE
Recent rolling excess versus the category median has deteriorated.
16 Oct 2026